How next-generation sequencing will change the treatment of multiple myeloma
The biology of the plasma cell and drug targets in multiple myeloma
Side effects of panobinostat in multiple myeloma
Minimal residue disease (MRD) in multiple myeloma
Myeloma 2016: Panel discussion on in vivo drug screening
Caroline Heckman et al.